Gordon Cheung

Title: Gordon Cheung: Innovator in Chimeric Antigen Receptor Technology

Introduction

Gordon Cheung is a prominent inventor based in London, GB. He has made significant contributions to the field of biotechnology, particularly in the development of chimeric antigen receptors (CARs) for cancer treatment. With a total of 2 patents, his work is paving the way for innovative therapies in oncology.

Latest Patents

Gordon Cheung's latest patents focus on a chimeric antigen receptor (CAR) that comprises a CD19-binding domain. This CAR includes a heavy chain variable region (VH) with specific complementarity determining regions (CDRs) and a light chain variable region (VL) with its own set of CDRs. The sequences for these regions are as follows: CDR1—GY-AFSSS (SEQ ID No. 1), CDR2—YPGDED (SEQ ID No. 2), CDR3—SLLYGDYLDY (SEQ ID No. 3) for the heavy chain, and CDR1—SASSSVSYMH (SEQ ID No. 4), CDR2—DTSKLAS (SEQ ID No. 5), CDR3—QQWNINPLT (SEQ ID No. 6) for the light chain. This invention also includes a cell that comprises such a CAR, which is intended for use in treating cancer, particularly B cell malignancies.

Career Highlights

Throughout his career, Gordon Cheung has worked with notable companies such as UCL Business Plc and Autolus Limited. His experience in these organizations has contributed to his expertise in the field of biotechnology and patent development.

Collaborations

Gordon has collaborated with several professionals in his field, including Martin Pulé and Leila Mekkaoui. These collaborations have further enhanced his research and development efforts in innovative cancer therapies.

Conclusion

Gordon Cheung is a key figure in the advancement of chimeric antigen receptor technology, with a focus on improving cancer treatment options. His patents and collaborations reflect his commitment to innovation in the biotechnology sector.